The emergence of the CRISPR-Cas system as a technology has transformed our ability to modify nucleic acids. Prokaryotes evolved one member of this family, CRISPR-Cas 10 effector, Cas13a, as an RNA-guided ribonuclease that protects them from invading bacteriophages. Here, we demonstrate that Cas13a can be programmed to target eukaryotic viral pathogens, influenza virus A (IVA) and human respiratory syncytial virus (hRSV) in human cells. We designed synthetic mRNA coding for Cas13a, which when guided by CRISPR RNAs (crRNA) to target influenza virus or hRSV RNA, significantly mitigates these infections both 15 prophylactically, therapeutically, and over time. These data demonstrate a possible new class of synthetic mRNA-powered anti-viral interventions.
drug development is focused on small molecules and neutralizing antibodies, which require high doses or frequent re-dosing to obtain functional outcomes (6, 7) . Here, we propose a new paradigm for treating viral infections -the use of viral RNA activated RNases. RNA targeting enzymes can be advantageous over epitope blocking molecules. The stoichiometric limitations of antibody or small molecule neutralization can be overcome by utilizing RNA-targeting RNases, 25 allowing them to "keep up" with rapidly proliferating viral systems. Here, we designed synthetic mRNA encoding Cas13a, guided by CRISPR RNAs (crRNAs) to target both genomic and messenger RNA of influenza virus A/WSN/1933(H1N1), and hRSV A2. Overall, we demonstrate mRNA expressed Cas13a and crRNA mediated mitigation of influenza and hRSV infections, both as prophylaxis and therapy. 30 The discovery of RNA targeting class II -type VI CRISPR-Cas system in bacteria has engendered tremendous interest for potential applications. The CRISPR locus is composed of an array of direct repeats (DR), spacer sequences and the gene encoding Cas protein (8) . The effector type VI protein, Cas13a, processes DR of the precursor-crRNA (CRISPR-RNA) into mature crRNA. The Cas13a: crRNA complex activates when the target RNA (trRNA) 35 compliments with crRNA, and the Cas protein initiates RNA cleavage due to the higher eukaryote and prokaryote nucleotide-binding (HEPN) domain (8) . This property has been used to detect specific transcripts in mixtures of nucleic acids (9) . Later, these findings were applied to develop a platform for viral and bacterial pathogen detection system, termed as High-Sensitivity Enzymatic Reporter UnLOCKing (SHERLOCK) system (10, 11) . Cas13a activity has also been used for RNA knockdown of endogenous genes in human cell lines, and in the Oryza sativa (rice) protoplasm by transfecting with DNA vectors expressing Cas13a and crRNA (12) . In addition, it was demonstrated that if Nicotiana benthamiana is infiltrated with Cas13a DNA, it can interfere with green fluorescent protein expressing Turnip mosaic virus (13) . However, the utilization of this RNA targeting enzyme inhibiting RNA virus infections in human cells has not 5 been reported.
For the RNA targeting RNases to be safe and effective for therapeutic use, rapid but transient expression is preferred (14) . To achieve this, we opted for synthetic mRNA to express Cas13a. mRNA has the advantage of rapid translation of the desired protein and clearance, while it avoids safety concerns such as, genome integration, vertical and horizontal transmission, 10 and long-term persistence in the body (15). We synthesized mRNA coding for Leptotrichia buccalis Cas13a (9) and designed multiple crRNAs (CR) and target RNAs (trRNA or TR) corresponding to influenza virus A WSN/33 (IVA) or hRSV A2 genome and mRNA. The crRNA consists of conserved DRs that are specifically recognized by L. buccalis Cas13a followed by an influenza or hRSV virus targeting sequence. The mRNA encoding Cas13a
15
(modified with a V5 epitope tag) and Cas13a-NLS (with a V5 tag, and nuclear localization sequence each on C, and N termini) were modified during the in vitro transcription process to increase the translational efficiency and assuage innate immune responses.
Using the rabbit reticulocyte lysate, Cas13a and Cas13a-NLS mRNAs were translated in vitro and used to assess the RNA cleavage activity of Cas13a protein in conjunction with IVA 20 crRNAs and trRNAs (Fig. 1A) . crRNA and trRNA were derived from genome segments of IVA (Table S1 ). RNaseAlert™ substrate fluorescence was the output of RNA cleavage. Cas13a and Cas13a-NLS RNA cleavage generated fluorescence increased to its maximum during the initial 10 and 20 min period, respectively, and then gradually decreased over time due to depleted target RNA. The overall trend of RNA cleavage was similar for both the Cas13a (Fig. 1B) and Cas13a-25 NLS (Fig. 1C) . RNA cleavage was also observed when the lysate was interrogated by gel electrophoresis using a 15% TBE-Urea gel ( Fig. 1D and 1E ). Our results indicate that in vitro translated Cas13a mediated RNA cleavage is specific and occurred only when both the crRNA and trRNA were present. Our results corroborate previous findings of specific activation, when purified Cas13a protein was used (9) . The presence of yeast tRNA or cellular RNA in the within the cytoplasm, whereas Cas13a-NLS, was present in both the cytoplasm (as Cas13a is being synthesized) and, at 48 hr, within the nucleus (Fig. 2B ).
We then screened an array of crRNAs targeting multiple RNA segments to find candidate crRNAs that target and decrease IVA infections. A549 cells were simultaneously transfected with Cas13a or Cas13a-NLS mRNA and each crRNA followed by influenza virus infection (at 5 multiplicity of infection, MOI 0.01) (Fig. 2C) . Among all the crRNAs screened, the crRNA targeting the PB1 genome segment (gPB1) was found to reduce viral RNA copy most efficiently (Fig. 2D) . To demonstrate that the Cas13a:crRNA system impacts viral RNA and protein production, we performed immunofluorescence for Cas13a, IVA M2 protein (indicating viral assembly or disassembly sites(16)), followed by fluorescence in situ hybridization (FISH) for the 10 IVA genome. We observed that cells transfected with either the Cas13a or Cas13a-NLS mRNAs, and crRNA, targeting PB1 site, (gPB1 and mPB1 targeting PB1 mRNA) showed reduced IVA infection (Fig. 2E) , and localization of Cas13a to viral sites within the cytosol. We next investigated the time dependent degradation of viral RNA during the infection. We found that targeting either the gPB1 or mPB1 reduced viral copies by 0.96-1.21 log at 24h, 1.88-2.6 log at 15 48 h, but further reduced viral RNA copies by 3.53-3.8 logs at 72h for both Cas13a (Fig. 2F ) and Cas13a-NLS (Fig. 2G ). This data is noteworthy, as prolonged effect of Cas13a interrupts IVA replication and reduced the viral copies up to 72h.
The Cas13a activity was specific in cleaving IVA RNA and did not result in any detected off-target RNA cleavage. The transcriptome profile of cells transfected with Cas13a mRNA and 20 crRNA (PB1) at 8 and 24h post-delivery, with or without infection with IVA, showed no significant changes in endogenous gene expression ( fig. S4) . Similarly, specific endogenous mRNA knockdown in cells with no off-target activity was reported previously in Leptotrichia wadei Cas13a (12).
Next, we investigated a number of experimental conditions, in order to characterize the 25 performance of the Cas13a:crRNA system. We evaluated the effect of MOI, demonstrating that Cas13a:crRNAs targeting PB1 were able to reduce the influenza virus gene copies by 0.77-1.26 log 24h post transfection (Fig. 3A) , at MOI of 0.1 (Fig. 3B ) and 0.01 (Fig. 3C) , both physiologically relevant MOIs. We also observed that Cas13a: crRNA system effectively inhibits IVA in a normal human primary bronchial/tracheal epithelial cell model (Fig.3D) . As we have 30 demonstrated that the Cas13a: crRNA system mitigates IVA infections in a prophylactic manner, we sought to assess if the infection could be reduced in cells already infected with IVA. The cells infected with IVA (MOI 0.01) for 4h were later transfected with Cas13a/Cas13a-NLS mRNA and crRNA (gPB1 and mPB1) (Fig. 3E) , and the effect on IVA monitored for 72 hours. We observed a maximum of 0.74 log reduction in IVA copy numbers with either Cas13a (Fig. 3F) or 35 Cas13a-NLS (Fig. 3G ) after 48 and 1.47 log reduction after 72h of transfection.
We then evaluated the efficiency of Cas13a-crRNA on the IVA infection by transfecting the cells with Cas13a mRNA and crRNA for 24h, anticipating a decrease in expression of Cas13a (based on Fig. 2B) , and then infecting with influenza virus for 8h (Fig. 3H) . Under this condition, we still observed a maximum of 0.3 log reduction of IVA, thus underlining the 40 robustness of the Cas13a mediated targeting of IVA (Fig.3I ).
Cas13a-crRNA system offers potential resolve to target various viral species through the design of specific crRNAs. To demonstrate this, we designed crRNA against both the human respiratory syncytial virus (RSV) genome (gRSV) and the M2 mRNA (RSV-M2). Cells transfected with Cas13a mRNA and both crRNAs exhibited reduced RSV titers, both as prophylaxis (Fig. 3J-K) and post-infection (Fig. 3L-M) . There was maximum of 0.55 log reduction in Cas13a: crRNA when given prophylactically (Fig. 3K) . However, when infected with RSV before transfection, Cas13a: crRNA reduced RSV titer by 0.3-0.44 log in crRNA 1.1 and m1.1, given together, whereas viral titer in crRNAs targeting genome mRNA (1.1) and RSV 5 mRNA given individually was only 0.2-logs (Fig. 3M) . It should be noted that even though we only observed ~50% knockdown via prophylaxis in hRSV, these data were obtained with a firstgeneration guide, based only on the M2/L gene end sequence. In addition, in the cells receiving Cas13a:crRNA, the plaques were not only diminished in number but also in size, demonstrating lower cell-to-cell spread and possibly the generation of more defective interfering particles. 10 Overall, this result alone is extremely promising, as future unbiased guide screens against the hRSV genomic and mRNA will likely yield improved knockdown. These findings demonstrate the potential of the Cas13a: crRNA system as an antiviral approach, likely applicable to many viral pathogens.
Overall, our study clearly demonstrates that Cas13a mitigates IVA and hRSV infections 15 and has the potential to be used against other RNA viruses. With the help of epidemiological information through screening and sequencing of the viral pathogens, several crRNAs can be rapidly and easily designed and screened to offer flexibility to deal with genetic drift and shifts or even the emergence of a new viral threat. However, it should be noted that the mRNP secondary structure and protein content, as well as viral RNP genome organization may 20 influence the accessibility of crRNA and Cas13a for the target RNA. In our experiments, Cas13a cleavage of viral RNA was always successful, but viral RNPs, in the cell, were not always accessible. Thus, it is important to screen crRNAs in cells, considering these complexities; the development of high throughput screening methods for mining efficient crRNAs and those that address safety concerns will be critical to transforming this tool into a bona fide therapeutic 25 approach.
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Figures S1-S4 Tables S1-S3   30 External Databases S1 References (9, 17) infected with IVA for 8h. IVA gene PB1 copy numbers were significantly reduced in all treatment groups (I). The present Cas13a system was then adapted to prevent RSV infection, in both 4h transfection first-set-up (J-K) as well as 4h-infection first-set-up (L-M)). RSV infection was reduced up to 1-log when measured by plaque assay using Cas13a both prophylactically (K) and post-infection (M). Interestingly, RSV plaques in all treatment groups were reduced in both numbers and size. All the statistical analyses were performed using analysis of variance with multiple comparisons with appropriate post-test measurements. (* p≤ 0.05, **p≤ 0.005, ***p≤ 0.001 or ****p≤ 0.0001).
